The findings were reported in Science Translational Medicine. The researchers wanted to measure autoantibody levels in nasal ...

New research is providing a more precise prediction of COVID-19 severity that can be found by looking at autoantibodies in the nasal cavity, leading to more personalized treatment plans.

COVID-19 presents a broad range of symptoms, varying in intensity from mild to severe and even life-threatening.

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation at the American College of Rheumatology (ACR) Convergence 2024, taking place in ...

A wide variety of COVID-19 symptoms exist, ranging from mild to severe, and while current strains of the virus generally cause milder symptoms, those with co-morbidities are still at an exponentially ...

Dr. Ghosn said: “If this nasal autoantibody response turns out to be a common mechanism to protect us against other viral ...

In 2025, children within the TEDDY study will submit their final samples at research clinics in Sweden, Finland, Germany and the United States. The international study has provided a lot of new ...

The Leeds, England-based autoantibody profiling research services to pharmaceutical and biotechnology industry to enable delivery of precision medicine said it signed three new contracts with a total ...

Objectives Sjögren’s disease (SD) is an autoimmune disease affecting the exocrine glands that is associated with autoantibodies against Ro60/SS-A, anti-Ro52/TRIM21, La/SS-B and others. We examined the ...

As many in the type 1 diabetes community can attest, it can be difficult at first to understand the purpose of screening or ...

Objectives Systemic sclerosis (SSc) is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient ...

In addition to the share offers, Oncimmune recapitalised two-thirds of its debt, with EUR4.0 million in existing debt converted into equity at the same price of 15p per share. That will leave EUR4.0 ...